ChiCTR2600128212 Almonertinib Mesilate EGFR-Mutant NSCLC Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Move from a broad disease map to a decision-ready trial dossier. This focused report examines ChiCTR2600128212—A phase II study of Sacituzumab Tirumotecan combined with Almonertinib as first-line treatment for advanced NSCLC patients with high PD-L1 expression and EGFR mutations—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why ChiCTR2600128212 is a hot trial to watch

EGFR-Mutant NSCLC is no longer one homogeneous development market. The most consequential programs increasingly compete through a specific mechanism, biomarker, treatment line, delivery strategy or endpoint architecture. ChiCTR2600128212 is notable because it tests Almonertinib Mesilate, Sacituzumab tirumotecan in a Phase 2 design with Objective response rate, ORR as a primary decision variable. The wider PatSnap topic query returned 761 trial records and 2,193 result records, so differentiation depends on evidence quality rather than activity alone.

PatSnap Clinical Trials MCP makes the protocol fields machine-readable, while the companion asset and organization servers add mechanism and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The design should be read as an evidence architecture, not just a phase label. The primary endpoint—Objective response rate, ORR—determines what uncertainty this study can resolve. The reported time frame is Imaging-based tumor evaluations will be conducted at 8-week (±7 days) intervals during the initial 48-week period, followed by 12-week (±7 days) intervals thereafter.. Enrollment of 20 participants and geography in China shape statistical precision, operational risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.

Benchmark readouts in the same clinical field

• Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study (Phase 3): AE(led to discontinuation) = 5.0 % ; AE(led to discontinuation) = 13.0 % .
• Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD (Phase 2): ORR = 36.0 % ( 25 - 49); ORR = 43.0 % ( 32 - 55).
• Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy (Phase 3): Risk of confirmed deterioration(appetite loss): HR = 1.0(95.0% CI, 0.63 - 1.58); Risk of confirmed deterioration(appetite loss): HR = 1.0(95.0% CI, 0.63 - 1.58).

These result records are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, line of therapy, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.

Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Almonertinib Mesilate (Approved; EGFR L858R x EGFR T790M x EGFR-Ex19del); Sacituzumab tirumotecan (Approved; Top I x Trop-2).

Company & Deal Intelligence context: Affiliated Hospital of Hebei University — http://www.hbdxfy.cn.

The sponsor profile matters because a trial's strategic value depends on more than scientific rationale. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.

White space around this program

1. Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
2. Clinically interpretable endpoints: outcomes that connect biological activity with function, symptoms, survival or treatment burden.
3. Sequencing evidence: randomized data after the most relevant contemporary standard of care.
4. Broader external validity: evidence across additional geographies, demographic groups and real-world care settings.
5. Operational differentiation: a development path that closes the readout gap without sacrificing safety monitoring or durability.

What to monitor next

Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.

Bottom line

ChiCTR2600128212 is a focused lens on EGFR-Mutant NSCLC development. Its value will be determined by whether Almonertinib Mesilate can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from topic-level benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.